The United States Food and Drug Administration (US FDA) has approved VYKATâ„¢ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).
The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...